期刊
ACS SYNTHETIC BIOLOGY
卷 9, 期 6, 页码 1263-1269出版社
AMER CHEMICAL SOC
DOI: 10.1021/acssynbio.0c00097
关键词
CRISPR/Cas9; genomic safe harbor; HEK cells; recombinase-mediated cassette exchange; site-specific integration; therapeutic protein
资金
- National Research Foundation of Korea (NRF) - Korea government (MSIT) [2020R1A2C1003235, 2018R1C1B6001423]
- Novo Nordisk Foundation [NNF10CC1016517]
- National Research Foundation of Korea [2020R1A2C1003235, 2018R1C1B6001423] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Human cell lines are being increasingly used as host cells to produce therapeutic glycoproteins, due to their human glycosylation machinery. In an attempt to develop a platform for generating isogenic human cell lines producing therapeutic proteins based on targeted integration, three well-known human genomic safe harbors (GSHs)-AAVS1, CCRS, and human ROSA26 loci-were evaluated with respect to the transgene expression level and stability in human embryonic kidney (HEK293) cells. Among the three GSHs, the AAVS1 locus showed the highest eGFP expression with the highest homogeneity. Transgene expression at the AAVS1 locus was sustained without selection for approximately 3 months. Furthermore, the CMV promoter showed the highest expression, followed by the EF1 alpha, SV40, and TK promoters at the AAVS1 locus. Master cell lines were created using CRISPR/Cas9-mediated integration of the landing pad into the AAVS1 locus and were used for faster generation of recombinant cell lines that produce therapeutic proteins with recombinase-mediated cassette exchange.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据